In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer

Docetaxel (DOC) is used for the first-line treatment of castration resistant prostate cancer (CPRC). However, the therapeutic effects are limited, only about one half of patients respond to the therapy and severe side effects possibly lead to discontinuation of treatment. Therefore, actual research...

Descripción completa

Detalles Bibliográficos
Autores principales: Michalska, Marta, Schultze-Seemann, Susanne, Bogatyreva, Lioudmila, Hauschke, Dieter, Wetterauer, Ulrich, Wolf, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008379/
https://www.ncbi.nlm.nih.gov/pubmed/26968813
http://dx.doi.org/10.18632/oncotarget.8001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008379/
https://www.ncbi.nlm.nih.gov/pubmed/26968813
http://dx.doi.org/10.18632/oncotarget.8001

Ejemplares similares